Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs NovaBridge Biosciences (NBP)

Coherus Oncology, Inc. and NovaBridge Biosciences are both Biotechnology companies. NovaBridge Biosciences is the larger, with a market value of $99.9M against $90.0M — 1.1× the size. Coherus Oncology, Inc. grew revenue faster over the last twelve months: 44.4% against −91.8%. NovaBridge Biosciences has the higher net margin (0.00% vs −253.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 18 metrics below, NovaBridge Biosciences leads on 11 and Coherus Oncology, Inc. on 7.

Valuation

Metric CHRS NBP Biotechnology median
P/E n/m n/m 11.58
P/S 1.70 3.71 9.61
P/B 3.62 0.36 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m 2.75 0.72
EV/Sales 4.39 (5.41) 9.43
Earnings yield (165.05%) (55.28%) (32.28%)
Free cash flow yield (191.02%) (128.62%) (22.27%)

Profitability

Metric CHRS NBP Biotechnology median
Gross margin 69.81% 31.10% 68.81%
Operating margin (275.94%) 0.00% 0.00%
Net margin (253.43%) 0.00% 0.00%
Free cash flow margin (323.85%) 0.00% 0.00%
Return on equity (240.54%) 0.00% (50.30%)
Return on assets (39.54%) 0.00% (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS NBP Biotechnology median
Revenue growth (TTM) 44.36% (91.84%) 6.78%
EPS growth (last fiscal year) 472.00% (77.78%) 29.88%
Revenue growth, 5-year CAGR (38.41%) (40.00%) 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS NBP Biotechnology median
Debt to equity 2.08 0.00 0.00
Current ratio 1.51 7.64 4.74
Net debt to EBITDA 0.76 2.26 1.01

Dividend

Metric CHRS NBP Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric CHRS NBP Biotechnology median
Market cap 90.02m 99.88m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack